How is Octreotide (Sandostatin) administered?
This describes how Octreotide (Sandostatin) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous (IR) or intramuscular (LAR), on a tID for IR; once monthly for LAR schedule, generally over long-term in approved indications. Specific dosing is individual and beyond general information, and human evidence for Octreotide (Sandostatin) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous (IR) or intramuscular (LAR)
- Schedule: TID for IR; once monthly for LAR
- Cycle length: Long-term in approved indications
- Half-life: ~1.7 hours (immediate-release); LAR depot dosed every 4 weeks
References
- Octreotide therapy for acromegaly, long term outcome — Mercado M et al., JCEM, 2014
- Sandostatin LAR Depot (octreotide acetate) - FDA Label — FDA / DailyMed (Novartis Pharmaceuticals)
- Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system — Nunes VS et al., Pituitary, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Octreotide (Sandostatin)
Full Octreotide (Sandostatin) breakdownOctreotide (Sandostatin) what it's used forOctreotide (Sandostatin) side effectsOctreotide (Sandostatin) mistakes to avoidOctreotide (Sandostatin) who should avoid itOctreotide (Sandostatin) half-lifeOctreotide (Sandostatin) how long to workOctreotide (Sandostatin) legal statusOctreotide (Sandostatin) how it worksAsk the AI Coach
Last updated 2026-06-15.